India's Cipla to price remdesivir version for COVID-19 under $66 - Reuters
4:33am PDT - June 23rd, 2020 remdesivir - ReutersIndian drugmaker Cipla Ltd will price its generic version of Gilead Sciences Inc's antiviral drug remdesivir for use in COVID-19 patients at less than 5,000 rupees ($66), the company said.